Her 2 Positive Metastatic Breast Cancer

Size: px
Start display at page:

Download "Her 2 Positive Metastatic Breast Cancer"

Transcription

1 Her 2 Positive Metastatic Breast Cancer Alison Jones November 2013

2 Mrs Hermione Positive (then and now!) Diagnosed 2007 T2 N1 Mo ER ve; Her2 ve Mastectomy ANC; FEC/T Herceptin (12months) August 2010metastatic relapse node and lung PS1 Normal organ function What next?

3 Trastuzumab Combination Pivotal Trial: Overall Survival FISH FISH 1.0 Trast. CT (n = 176) CT (n = 169) 1.0 Trast. CT (n = 50) CT (n = 56) Probability of survival mo 26.2 mo RR = 0.71 p = mo 24.0 mo RR = 1.11 p = NS Months Months Update of Mass. Proc Am Soc Clin Oncol. 2001;20:22a. Abstract 85.

4 Majority of patients with ErbB2-positive MBC responding to trastuzumab plus taxane or vinorelbine 1 st -line progress within 1 year months ,3* Median TTP *ErbB2 IHC 3 subgroup 1. Burstein et al. Cancer 2007;110(5):965 72; 2. Slamon et al. N Engl J Med 2001;344:783 92; 3. Smith et al. Anticancer Drugs 2001;12(Suppl 4):S3 10; 4. Burstein et al. J Clin Oncol 2001;19: ; 5. Gasparini et al. Breast Cancer Res Treat 2007;110(5):965 72; 6. Pegram et al. J Clin Oncol ASCO Annual Meeting Proceedings 2007;25(18S): Abstract #LBA1008; 7. Marty et al. J Clin Oncol 2005;23: ; 8. Tedesco et al. J Clin Oncol 2004;22(6):1071 7

5 GBG-26 was the first randomised Phase III study to investigate continuation of Herceptin Progression under Herceptin-based 1st-line therapy taxane (n=114) a or progression under Herceptin monotherapy or non-taxane (n=42) R Xeloda 1,250 mg/m 2 bid d1-14 q21d continuation of Herceptin 6 mg/kg q3w (n=78) Xeloda 1,250 mg/m 2 bid d1-14 q21d (n=78) Primary endpoint: TTP a Includes 3 patients who received adjuvant Herceptin taxane R, randomisation von Minckwitz G et al ASCO 2008; Abs 26

6 Continuation of Herceptin prolongs time to progression by nearly 3 months Probability 1.0 Herceptin Xeloda (n=78) Xeloda (n=78) X: 5.6 ( ) mos XH: 8.2 ( ) mos HR=0.69 (2-sided p=0.034; 1-sided p=0.015) a 8.2 a Time from 1st progression (months) a Median TTP in months HR, hazard ratio von Minckwitz G et al ASCO 2008; Abs 26

7 Mrs Hermione Positive (situation in 2011) First line taxane plus herceptin with herceptin until disease progression At progression (outside CNS) apply for capecitabine plus lapatinib via Cancer Drugs fund At futher progrssion stop HER 2 targeted therapy (reluctantly) and unless there is a targeted trail available use standard@ chemotherapy and pray!

8 Mrs Hermione Positive (then and now!) Diagnosed 2010 T2 N1 Mo ER ve; Her2 ve Mastectomy ANC; FEC/T Herceptin (12months) August 2013 metastatic relapse node and lung PS1 Normal organ function What next?

9 CLEOPATRA (WO20698) HER2ve MBC (n=808) R Docetaxel trastuzumab placebo Docetaxel trastuzumab pertuzumab» Primary endpoint: PFS (independent review)» Secondary endpoints: Overall survival PFS (investigator assessment) Objective response rate and duration of response Safety profile Time to symptom progression (FACT Trial Outcome Index) Evaluate biomarkers and correlate with clinical outcomes» Enrolment stratified by: Prior treatment for breast cancer Geographic region FACT=Functional assessment of cancer therapy, PFS=progression-free survival

10 Primary endpoint: Independently assessed PFS n = 433 PFS events Progression-free survival (%) n at risk Pla T D Ptz T D: median 18.5 months Pla T D: median 12.4 months Time (months) Ptz 10 T D HR = % CI p< D, docetaxel; PFS, progression-free survival; Pla, placebo; Ptz, pertuzumab; T, trastuzumab = 6.1 months Stratified by prior treatment status and region

11 What to do at first relapse? Lapatinib plus capectiabine TDM-1? Trastuzumab plus laptinib? And then what to do at next relapse?

12 T-DM1 Structure Target expression: HER2 Monoclonal antibody: trastuzumab (Herceptin ) Cytotoxic agent: DM1 Highly potent cytotoxic agent Linker: MCC Systemically stable T-DM1 Average drug:antibody ratio 3.5:1 12

13 EMILIA Phase III (TDM4370g) HER2-positive (centrally confirmed) locally advanced or MBC (n=980) R T-DM1 q3w Lapatanib capecitabine q3w Treatment continues until disease progression or unmanageable toxicity No provision for crossover Primary endpoints: PFS (by IRF) OS Safety Secondary endpoints: QoL FACT-B Key inclusion criteria Prior treatment to include a taxane and trastuzumab in adjuvant, locally advanced or metastatic setting Documented progression of disease during or after treatment for advanced/metastatic disease, or within 6 months of completing adjuvant therapy Silent as to line of therapy but assume majority of patients will be 2 nd (or 2 nd /3 rd )-line PFS=progression-free survival; IRF=independent review facility; OS=overall survival; QoL=quality of life; FACT-B=functional assessment of cancer therapy for breast cancer

14 Key findings: progression-free survival by independent and investigator review Blackwell KL, et al. ASCO 2012;30:LBA1.

15 Special cases Relapse on or within 12months of adjuvant treatment (pertuzumab not available through CDF) ER HER2 metastatic breast cancer (role of dual targeting) CNS only metastases Can we ever stop Trastuzumab in the metstatic setting?

16 HER2 breast Cancer; Keep the brake on HER2!

Advanced HER2+ Breast Cancer: New Options and How to Deploy Them. José Baselga MD, PhD

Advanced HER2+ Breast Cancer: New Options and How to Deploy Them. José Baselga MD, PhD Advanced HER2 Breast Cancer: New Options and How to Deploy Them José Baselga MD, PhD HER2 signaling results in a multitude of cellular effects, including increased cellular proliferation HER2 HER3 RAS

More information

Update in the treatment of Her2- overexpressing breast cancers. Fabrice ANDRE Institut Gustave Roussy Villejuif, France

Update in the treatment of Her2- overexpressing breast cancers. Fabrice ANDRE Institut Gustave Roussy Villejuif, France Update in the treatment of Her2- overexpressing breast cancers Fabrice ANDRE Institut Gustave Roussy Villejuif, France Questions Should tumors

More information

Update on the Management of HER2+ Breast Cancer. Christian Jackisch, MD, PhD Sana Klinikum Offenbach Offenbach, Germany

Update on the Management of HER2+ Breast Cancer. Christian Jackisch, MD, PhD Sana Klinikum Offenbach Offenbach, Germany Update on the Management of HER2+ Breast Cancer Christian Jackisch, MD, PhD Sana Klinikum Offenbach Offenbach, Germany Outline Treatment strategies for HER2-positive metastatic breast cancer since First

More information

HER2-Targeted Rx. An Historical Perspective

HER2-Targeted Rx. An Historical Perspective HER2-Targeted Rx An Historical Perspective Trastuzumab: Front Line Rx for MBC Median 20.3 v. 25.1 mo P = 0.046 HR 0.8 65% of control patients crossed over Slamon D, et al. N Engl J Med, 2001; 344:783 Trastuzumab:Front-line

More information

HER2-positive Breast Cancer

HER2-positive Breast Cancer HER2-positive Breast Cancer Multiple choices what to use when? Thomas Ruhstaller Brustzentrum St. Gallen Adjuvant setting NCIC MA5 N Engl J Med 06, 2103 6 x CEF can 6 x CMF oral HER2 + pg schlecht in allen

More information

Targe:ng HER2 in Metasta:c Breast Cancer in 2014

Targe:ng HER2 in Metasta:c Breast Cancer in 2014 Targe:ng HER2 in Metasta:c Breast Cancer in 2014 Kimberly L. Blackwell MD Professor Department of Medicine and Radia:on Oncology Duke University Medical Center Director, Breast Cancer Program Duke Cancer

More information

Evolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents

Evolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents Evolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents Kimberly L. Blackwell MD Professor Department of Medicine and Radiation Oncology Duke University Medical Center

More information

New Drug Development in HER2+ Breast Cancer

New Drug Development in HER2+ Breast Cancer New Drug Development in HER2+ Breast Cancer Philippe Aftimos, M.D. Senior Research Physician Clinical Pharmacology Unit Institut Jules Bordet Background Amplification of HER2 occurs in approximately 20%

More information

Expanding Therapeutic Strategies for HER2-Positive Metastatic Breast Cancer

Expanding Therapeutic Strategies for HER2-Positive Metastatic Breast Cancer Expanding Therapeutic Strategies for HER2-Positive Metastatic Breast Cancer Sara A. Hurvitz, MD, FACP Associate Professor of Medicine University of California Los Angeles Los Angeles, California Trastuzumab

More information

Immunoconjugates in Both the Adjuvant and Metastatic Setting

Immunoconjugates in Both the Adjuvant and Metastatic Setting Immunoconjugates in Both the Adjuvant and Metastatic Setting Mark Pegram, M.D. Director, Stanford Breast Oncology Program Co-Director, Molecular Therapeutics Program Trastuzumab Treatment of Breast Tumor

More information

Her 2 Positive Advanced Breast Cancer: From Evidence to Practice

Her 2 Positive Advanced Breast Cancer: From Evidence to Practice Her 2 Positive Advanced Breast Cancer: From Evidence to Practice Sunil Verma MD, FRCP(C) Medical Director, Tom Baker Cancer Center Professor and Head, Department of Oncology Cumming School of Medicine,

More information

Overcoming resistance to endocrine or HER2-directed therapy

Overcoming resistance to endocrine or HER2-directed therapy Overcoming resistance to endocrine or HER2-directed therapy Jane Lowe Meisel, MD Assistant Professor of Hematology and Medical Oncology Winship Cancer Institute at Emory University 1 Background While most

More information

PROGNOSTICO DE PACIENTES COM CA DE MAMA METASTATICO HER2+: PODEMOS FAZER MAIS? TDM-1 AND BEYOND!

PROGNOSTICO DE PACIENTES COM CA DE MAMA METASTATICO HER2+: PODEMOS FAZER MAIS? TDM-1 AND BEYOND! II Simpósio Internacional de Câncer de Mama para o Oncologista Clínico PROGNOSTICO DE PACIENTES COM CA DE MAMA METASTATICO HER2+: PODEMOS FAZER MAIS? TDM-1 AND BEYOND! INGRID A. MAYER, MD, MSCI Assistant

More information

A vision for HER2 future

A vision for HER2 future School of Medical Oncology Department of Medical and Biological Sciences - University of Udine Department of Oncology - University Hospital of Udine A vision for HER2 future Current therapeutic algorithm

More information

New Targeted Agents Demonstrate Greater Efficacy and Tolerability in the Treatment of HER2-positive Breast Cancer

New Targeted Agents Demonstrate Greater Efficacy and Tolerability in the Treatment of HER2-positive Breast Cancer New Evidence reports on presentations given at ASCO 2012 New Targeted Agents Demonstrate Greater Efficacy and Tolerability in the Treatment of HER2-positive Breast Cancer Presentations at ASCO 2012 Breast

More information

Systemic Therapy of HER2-positive Breast Cancer

Systemic Therapy of HER2-positive Breast Cancer Systemic Therapy of HER2-positive Breast Cancer Tanja Cufer, MD, PhD University Clinic Golnik, Medical Faculty Ljubljana, Slovenia ESO ESMO Masterclass, Belgrade 2017 Relative Risk HER2-positive Breast

More information

The next wave of successful drug therapy strategies in HER2-positive breast cancer. Hans Wildiers University Hospitals Leuven Belgium

The next wave of successful drug therapy strategies in HER2-positive breast cancer. Hans Wildiers University Hospitals Leuven Belgium The next wave of successful drug therapy strategies in HER2-positive breast cancer Hans Wildiers University Hospitals Leuven Belgium Trastuzumab in 1st Line significantly improved the prognosis of HER2-positive

More information

Cancer du sein métastatique et amélioration de la survie Pr. X. Pivot

Cancer du sein métastatique et amélioration de la survie Pr. X. Pivot Cancer du sein métastatique et amélioration de la survie Pr. X. Pivot Date of preparation: November 2015. EU0250i TTP/PFS Comparaisons First line metastatic breast cancer Monotherapy Docetaxel Chan 1999

More information

William J. Gradishar MD

William J. Gradishar MD Northwestern University Feinberg School of Medicine Management of HER2+ MBC SOBO 2012 William J. Gradishar MD Betsy Bramsen Professor of Breast Oncology Director, Maggie Daley Center for Women s Cancer

More information

Recent advances in the management of metastatic breast cancer in older adults

Recent advances in the management of metastatic breast cancer in older adults Recent advances in the management of metastatic breast cancer in older adults Laura Biganzoli Medical Oncology Dept New Hospital of Prato Istituto Toscano Tumori Italy Important recent advances in the

More information

Systemic therapy for HER2+ Advanced Breast Cancer

Systemic therapy for HER2+ Advanced Breast Cancer Systemic therapy for HER2+ Advanced Breast Cancer F. Cardoso, MD Director, Breast Unit, Champalimaud Clinical Center, Lisbon, Portugal ESMO Board of Directors & NR Committee Chair ESO Breast Cancer Program

More information

Nuovo paradigma terapeutico nel trattamento del carcinoma mammario HER2+ metastatico: dagli studi alla pratica clinica Prima linea di trattamento

Nuovo paradigma terapeutico nel trattamento del carcinoma mammario HER2+ metastatico: dagli studi alla pratica clinica Prima linea di trattamento Nuovo paradigma terapeutico nel trattamento del carcinoma mammario HER2+ metastatico: dagli studi alla pratica clinica Prima linea di trattamento Prof. Sabino De Placido Dip. di Endocrinologia ed Oncologia

More information

Choice of Chemotherapy Combination with Targeted Agent in Metastatic Breast Cancer

Choice of Chemotherapy Combination with Targeted Agent in Metastatic Breast Cancer Choice of Chemotherapy Combination with Targeted Agent in Metastatic Breast Cancer Department of Oncology National Taiwan University Hospital Yen-Shen Lu MD., PhD. Targeted Therapy for Breast Cancer Anti-HER

More information

Systemic Therapy of HER2-positive Breast Cancer

Systemic Therapy of HER2-positive Breast Cancer Systemic Therapy of HER2-positive Breast Cancer Tanja Cufer, MD, PhD University Clinic Golnik, Medical Faculty Ljubljana, Slovenia ESO ESMO Masterclass, Belgrade 2018 HER2-positive Breast Cancer Adjuvant

More information

Systemic therapy: HER-2 update. Hans Wildiers Multidisciplinair Borst Centrum/Algemene medische oncologie UZ Leuven

Systemic therapy: HER-2 update. Hans Wildiers Multidisciplinair Borst Centrum/Algemene medische oncologie UZ Leuven Systemic therapy: HER-2 update Hans Wildiers Multidisciplinair Borst Centrum/Algemene medische oncologie UZ Leuven New drugs Strategic issues Specific anti-her2 drugs Lapa$nib /Nera$nib Baselga & Swain,

More information

Media Release. Basel, 3 June 2012

Media Release. Basel, 3 June 2012 Media Release Basel, 3 June 2012 Roche s targeted investigational breast cancer medicine, trastuzumab emtansine (T-DM1), reduced the risk of cancer worsening or death by 35 percent in pivotal phase III

More information

DR LUIS MANSO UNIDAD TUMORES DE MAMA Y GINECOLÓGICOS HOSPITAL 12 DE OCTUBRE MADRID

DR LUIS MANSO UNIDAD TUMORES DE MAMA Y GINECOLÓGICOS HOSPITAL 12 DE OCTUBRE MADRID DR LUIS MANSO UNIDAD TUMORES DE MAMA Y GINECOLÓGICOS HOSPITAL 12 DE OCTUBRE MADRID RESUMEN DE ARTICULOS THERESA BOLERO 3 NOAH UP-DATE GEPAR SIXTO RADIOTHERAPY EBCTCG CTCs MISCELANEAS Lancet Oncol 2014;

More information

Metastasi viscerali: altre opzioni oltre la chemioterapia. Ormonoterapia e Agentianti-Her2. - Valentina Sini -

Metastasi viscerali: altre opzioni oltre la chemioterapia. Ormonoterapia e Agentianti-Her2. - Valentina Sini - Metastasi viscerali: altre opzioni oltre la chemioterapia. Ormonoterapia e Agentianti-Her2 - Valentina Sini - Metastatic Breast Cancer ER- Her2-20% ER- Her2+ ER+ Her2+ 5% 15% ER+ Her2- ER+ Her2+ ER- Her2+

More information

PIK3CA Mutations in HER2-Positive Breast Cancer

PIK3CA Mutations in HER2-Positive Breast Cancer 2016.4.29. GBCC PIK3CA Mutations in HER2-Positive Breast Cancer Seock-Ah Im, MD, PhD. Department of Internal Medicine Seoul National University Hospital Contents Introduction TCGA data HER2 signaling pathway

More information

Emerging Agents in HER2-positive Disease. Mary Cianfrocca, DO Director, Breast Oncology Program Banner MD Anderson Cancer Center Gilbert, AZ

Emerging Agents in HER2-positive Disease. Mary Cianfrocca, DO Director, Breast Oncology Program Banner MD Anderson Cancer Center Gilbert, AZ Emerging Agents in HER2-positive Disease Mary Cianfrocca, DO Director, Breast Oncology Program Banner MD Anderson Cancer Center Gilbert, AZ Signal Transduction by the HER Family and Potential Mechanisms

More information

Breast cancer update. Iryna Kuchuk, MD Oncology department Meir Medical Center

Breast cancer update. Iryna Kuchuk, MD Oncology department Meir Medical Center Breast cancer update Iryna Kuchuk, MD Oncology department Meir Medical Center Overview Cancer Death Rates* Among Women, US,1930-2009 Factors Associated with Reduction In Breast Cancer Mortality Early

More information

Advances in the Management of Metastatic Her 2 Positive Breast Cancer

Advances in the Management of Metastatic Her 2 Positive Breast Cancer Advances in the Management of Metastatic Her 2 Positive Breast Cancer Sunil Verma MD, MSEd, FRCPC Medical Oncologist Research Lead, Division of Medical Oncology Chair, Breast Medical Oncology Sunnybrook

More information

DEBATE: NUEVOS TRATAMIENTOS EN CÁNCER DE MAMA POSICIONAMIENTO Y ALGORITMO TERAPÉUTICO CÁNCER DE MAMA HER 2 POSITIVO

DEBATE: NUEVOS TRATAMIENTOS EN CÁNCER DE MAMA POSICIONAMIENTO Y ALGORITMO TERAPÉUTICO CÁNCER DE MAMA HER 2 POSITIVO DEBATE: NUEVOS TRATAMIENTOS EN CÁNCER DE MAMA POSICIONAMIENTO Y ALGORITMO TERAPÉUTICO CÁNCER DE MAMA HER 2 POSITIVO DEBATE: NUEVOS TRATAMIENTOS EN CÁNCER DE MAMA POSICIONAMIENTO Y ALGORITMO TERAPÉUTICO

More information

Present and emerging treatment options in Her-2/neu overexpressing metastatic breast cancer

Present and emerging treatment options in Her-2/neu overexpressing metastatic breast cancer Present and emerging treatment options in Her-2/neu overexpressing metastatic breast cancer Christoph C. Zielinski Clinical Division of Oncology, Department of Medicine I and Comprehensive Cancer Center,

More information

Innovations In The Management Of

Innovations In The Management Of Innovations In The Management Of HER2+ Breast Cancer Dr. Sandeep Goyle Consultant Medical Oncologist Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute Mumbai, India Introduction - Self

More information

Breast : ASCO Abstracts for Review

Breast : ASCO Abstracts for Review Breast : ASCO 2011 Susana Campos, MD, MPH Dana Farber Cancer Institute Abstracts for Review Prevention Neoadjuvant Metastatic Brain mets LBA 504: Exemestane for primary prevention of breast cancer in postmenopausal

More information

Karcinom dojke. PANEL: Semir Bešlija, Zdenka Gojković, Robert Šeparović, Tajana Silovski

Karcinom dojke. PANEL: Semir Bešlija, Zdenka Gojković, Robert Šeparović, Tajana Silovski Karcinom dojke PANEL: Semir Bešlija, Zdenka Gojković, Robert Šeparović, Tajana Silovski MBC: HER2 PHEREXA: Study Design Multicenter, randomized, open-label phase III trial Stratified by prior CNS disease,

More information

Contemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer

Contemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer Contemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer Hope S. Rugo, MD Professor of Medicine Director, Breast Oncology and Clinical Trials Education University of California

More information

Enfermedad con sobreexpresión de HER-2 neu

Enfermedad con sobreexpresión de HER-2 neu Enfermedad con sobreexpresión de HER-2 neu Elsa Dalmau Parc Taulí Sabadell. Hospital Universitari. Enfermedad con sobreexpresión de HER-2 neu ÍNDICE Neoadyuvancia Adyuvancia Enfermedad avanzada Enfermedad

More information

José Baselga, MD, PhD

José Baselga, MD, PhD i n t e r v i e w José Baselga, MD, PhD Dr Baselga is Physician-in-Chief at Memorial Sloan-Kettering Cancer Center in New York, New York. Tracks 1-15 Track 1 Track 2 Track 3 Track 4 Track 5 Track 6 Track

More information

Jonathan Dickinson, LCL Xeloda

Jonathan Dickinson, LCL Xeloda Xeloda A blockbuster in the making Jonathan Dickinson, LCL Xeloda Xeloda unique tumor-activated mechanism Delivering more cancer-killing agent straight into cancer Highly effective comparable efficacy

More information

ESMO 2017, Madrid, Spain Dr. Loredana Vecchione Charite Comprehensive Cancer Center, Berlin HIGHLIGHTS ON CANCERS OF THE UPPER GI TRACT

ESMO 2017, Madrid, Spain Dr. Loredana Vecchione Charite Comprehensive Cancer Center, Berlin HIGHLIGHTS ON CANCERS OF THE UPPER GI TRACT ESMO 2017, Madrid, Spain Dr. Loredana Vecchione Charite Comprehensive Cancer Center, Berlin HIGHLIGHTS ON CANCERS OF THE UPPER GI TRACT DOCETAXEL, OXALIPLATIN AND FLUOROURACIL/LEUCOVORIN (FLOT) FOR RESECTABLE

More information

Sustained benefits for women with HER2-positive early breast cancer JORGE MADRID BIG GOCCHI PROTOCOLO HERA

Sustained benefits for women with HER2-positive early breast cancer JORGE MADRID BIG GOCCHI PROTOCOLO HERA Sustained benefits for women with HER2-positive early breast cancer JORGE MADRID BIG GOCCHI PROTOCOLO HERA The fascinating history of Herceptin 1981 1985 1987 1990 1992 1998 2000 2005 2006 2008 2011 Murine

More information

非臨床試験 臨床の立場から 京都大学医学部附属病院戸井雅和

非臨床試験 臨床の立場から 京都大学医学部附属病院戸井雅和 資料 2 2 非臨床試験 臨床の立場から 京都大学医学部附属病院戸井雅和 1 Preclinical studies Therapeutic Window: Efficacy/Toxicity Disease Specificity Subtype Specificity Combination: Concurrent/Sequential Therapeutic situation: Response/

More information

Review of adjuvant and neo-adjuvant abstracts from SABCS 2011 January 7 th 2012

Review of adjuvant and neo-adjuvant abstracts from SABCS 2011 January 7 th 2012 Review of adjuvant and neo-adjuvant abstracts from SABCS 2011 January 7 th 2012 Ruth M. O Regan, MD Professor and Vice-Chair for Educational Affairs, Department of Hematology and Medical Oncology, Emory

More information

National Horizon Scanning Centre. Bevacizumab (Avastin) in combination with non-taxanes for metastatic breast cancer - first line therapy

National Horizon Scanning Centre. Bevacizumab (Avastin) in combination with non-taxanes for metastatic breast cancer - first line therapy Bevacizumab (Avastin) in combination with non-taxanes for metastatic breast cancer - first line therapy December 2007 This technology summary is based on information available at the time of research and

More information

Metronomic chemotherapy for breast cancer

Metronomic chemotherapy for breast cancer Metronomic chemotherapy for breast cancer M. Colleoni International Breast Cancer Study Group (IBCSG), Division of Medical Senology, European Institute of Oncology Metronomic Scheduling and Inhibition

More information

Resistance to anti-her2 therapies. Service d Oncologie Médicale

Resistance to anti-her2 therapies. Service d Oncologie Médicale Resistance to anti-her2 therapies Pr David Khayat Service d Oncologie Médicale Groupe Hospitalier Pitié Salpêtrière -Paris Disclosure statment Trastuzumab in HER2+ MBC A major impact but resistance will

More information

Biomarkers for HER2-directed Therapies : Past Failures and Future Perspectives

Biomarkers for HER2-directed Therapies : Past Failures and Future Perspectives Biomarkers for HER2-directed Therapies : Past Failures and Future Perspectives Ian Krop Dana-Farber Cancer Institute Harvard Medical School Inchon 2018 Adjuvant Trastuzumab Improves Outcomes in HER2+ Breast

More information

Targeted Agents In Breast Cancer. Wonderful Music With New Instruments

Targeted Agents In Breast Cancer. Wonderful Music With New Instruments Targeted Agents In Breast Cancer Wonderful Music With New Instruments 1 Trends In Cancer Mortality In Women in US At This Rate We Will Beat Breast Cancer In 2040 Is the cause screening?? Is the cause better

More information

Herceptin Pivotal Studies

Herceptin Pivotal Studies Herceptin Pivotal Studies Nuhad K Ibrahim, MD, FACP Associate Professor of Medicine Breast Medical Oncology Department MD Anderson Cancer Center Houston, TX, USAE-mail: nibrahim@mdanderson.org Herceptin

More information

Lo studio BOLERO-1 Quali potranno essere le future ricadute nella pratica clinica? Antonella Ferro UO Oncologia Medica Trento

Lo studio BOLERO-1 Quali potranno essere le future ricadute nella pratica clinica? Antonella Ferro UO Oncologia Medica Trento Lo studio BOLERO-1 Quali potranno essere le future ricadute nella pratica clinica? Antonella Ferro UO Oncologia Medica Trento TRASTUZUMAB most important breakthrough in the management of BC Trastuzumab

More information

4, :00 PM 9:00 PM

4, :00 PM 9:00 PM Consensus or Controversy? Clinical Investigators Provide Their Perspectives on Practical Issues and Research Questions in the Management of Breast Cancer Robert W Carlson, MD John Crown, MD Charles E Geyer

More information

Common disease 175,000 new cases/year 44,000 deaths/year Less than 10% with newly diagnosed at presentation have stage IV disease Chronic disease,

Common disease 175,000 new cases/year 44,000 deaths/year Less than 10% with newly diagnosed at presentation have stage IV disease Chronic disease, Chemotherapy for Metastatic Breast Cancer: Recent Results HARMESH R. NAIK, MD. Karmanos Cancer Institute and St. Mary Hospital Metastatic breast cancer (MBC) Common disease 175,000 new cases/year 44,000

More information

Optimizing anti-her-2 therapies for ABC Potential role of immunotherapy. Javier Cortes, Ramon y

Optimizing anti-her-2 therapies for ABC Potential role of immunotherapy. Javier Cortes, Ramon y Optimizing anti-her-2 therapies for ABC Potential role of immunotherapy Javier Cortes, Ramon y Cajal University Hospital, Madrid, Spain Vall d Hebron Institute of Oncology (VHIO), Medica Scientia Innovation

More information

Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.

Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509. Efficacy Results from the ToGA Trial: A Phase III Study of Trastuzumab Added to Standard Chemotherapy in First-Line HER2- Positive Advanced Gastric Cancer Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.

More information

Customizing Therapeutic Strategies in the Management of Metastatic Breast Cancer

Customizing Therapeutic Strategies in the Management of Metastatic Breast Cancer Customizing Therapeutic Strategies in the Management of Metastatic Breast Cancer Vandana G Abramson, MD Assistant Professor of Medicine Division of Hematology/Oncology Vanderbilt University Breast Cancer

More information

Cáncer de mama HER2+/RE+ vs HER2+/RE : Una misma enfermedad? Dra E. Ciruelos Departamento de Oncología Médica Hospital Universitario 12 de Octubre

Cáncer de mama HER2+/RE+ vs HER2+/RE : Una misma enfermedad? Dra E. Ciruelos Departamento de Oncología Médica Hospital Universitario 12 de Octubre Cáncer de mama HER2+/RE+ vs HER2+/RE : Una misma enfermedad? Dra E. Ciruelos Departamento de Oncología Médica Hospital Universitario 12 de Octubre Recurrence of HER2-positive breast cancer (A) Time to

More information

HER2 Positive Breast Cancer

HER2 Positive Breast Cancer HER2 Positive Breast Cancer Charles E. Geyer, Jr. MD, FACP Professor of Medicine Division of Hematology, Oncology and Palliative Care Virginia Commonwealth University Associate Director of Clinical Research

More information

TRANSPARENCY COMMITTEE

TRANSPARENCY COMMITTEE The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 19 March 2014 KADCYLA 100 mg, powder for concentrate for solution for infusion One 15-ml vial (CIP: 34009 585,760

More information

Update HER2. Rupert Bartsch. Department of Medicine 1, Clinical Division of Oncology Comprehensive Cancer Center Vienna Medical University of Vienna

Update HER2. Rupert Bartsch. Department of Medicine 1, Clinical Division of Oncology Comprehensive Cancer Center Vienna Medical University of Vienna Update HER2 Rupert Bartsch Department of Medicine 1, Clinical Division of Oncology Comprehensive Cancer Center Vienna Medical University of Vienna HER2: A Unique Story of Success Analysis of outcome in

More information

Novel Chemotherapy Agents for Metastatic Breast Cancer. Joanne L. Blum, MD, PhD Baylor-Sammons Cancer Center Dallas, TX

Novel Chemotherapy Agents for Metastatic Breast Cancer. Joanne L. Blum, MD, PhD Baylor-Sammons Cancer Center Dallas, TX Novel Chemotherapy Agents for Metastatic Breast Cancer Joanne L. Blum, MD, PhD Baylor-Sammons Cancer Center Dallas, TX New Chemotherapy Agents in Breast Cancer New classes of drugs Epothilones Halichondrin

More information

Maintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute

Maintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute Maintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute e.smit@nki.nl Evolution of front line therapy in NSCLC unselected pts

More information

Advances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings. Eve Rodler, MD University of California at Davis October 2016

Advances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings. Eve Rodler, MD University of California at Davis October 2016 Advances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings Eve Rodler, MD University of California at Davis October 2016 17th Annual Advances in Oncology September 30-October 1, 2016

More information

HER2 Biology and Treatment in Breast Cancer

HER2 Biology and Treatment in Breast Cancer HER2 Biology and Treatment in Breast Cancer Sandra M. Swain, MD, FACP Director, Washington Cancer Institute Washington Hospital Center Professor of Medicine Georgetown University Washington DC Off-Label

More information

METRIC Study Key Eligibility Criteria

METRIC Study Key Eligibility Criteria The METRIC Study METRIC Study Key Eligibility Criteria The pivotal METRIC Study is evaluating glembatumumab vedotin in patients with gpnmb overexpressing metastatic triple-negative breast cancer (TNBC).

More information

Should pertuzumab be used as part of neoadjuvant treatment prior to the release of the APHINITY trial results?

Should pertuzumab be used as part of neoadjuvant treatment prior to the release of the APHINITY trial results? Commentary Should pertuzumab be used as part of neoadjuvant treatment prior to the release of the APHINITY trial results? Tom Wei-Wu Chen 1, Ching-Hung Lin 1,2, Chiun-Sheng Huang 3 1 Department of Oncology,

More information

SYSTEMIC THERAPY FOR HER-2+ ABC

SYSTEMIC THERAPY FOR HER-2+ ABC SYSTEMIC THERAPY FOR HER-2+ ABC F. Cardoso, MD Director, Breast Unit, Champalimaud Clinical Center, Lisbon, Portugal ESO Breast Cancer Program Coordinator ESMO Board of Directors & NR Committee Chair EORTC

More information

ASCO and San Antonio Updates

ASCO and San Antonio Updates ASCO and San Antonio Updates 30 th Annual Miami Breast Cancer Conference March 7-10, 2013 Debu Tripathy, MD Professor of Medicine University of Southern California Norris Comprehensive Cancer Center Breakthroughs

More information

2 nd line Therapy and Beyond NSCLC. Alan Sandler, M.D. Oregon Health & Science University

2 nd line Therapy and Beyond NSCLC. Alan Sandler, M.D. Oregon Health & Science University 2 nd line Therapy and Beyond NSCLC Alan Sandler, M.D. Oregon Health & Science University Treatment options for advanced or metastatic (stage IIIb/IV) NSCLC Suitable for chemotherapy Diagnosis Unsuitable/unwilling

More information

Targeting the Oncogenic Pathway as Opposed to the Primary Tumor Site: HER2 as an Example

Targeting the Oncogenic Pathway as Opposed to the Primary Tumor Site: HER2 as an Example Targeting the Oncogenic Pathway as Opposed to the Primary Tumor Site: HER2 as an Example Dennis J Slamon, MD, PhD Professor of Medicine Chief, Division of Hematology/Oncology; Director of Clinical/Translational

More information

Policy No: dru281. Medication Policy Manual. Date of Origin: September 24, Topic: Perjeta, pertuzumab. Next Review Date: May 2015

Policy No: dru281. Medication Policy Manual. Date of Origin: September 24, Topic: Perjeta, pertuzumab. Next Review Date: May 2015 Medication Policy Manual Topic: Perjeta, pertuzumab Committee Approval Date: May 9, 2014 Policy No: dru281 Date of Origin: September 24, 2012 Next Review Date: May 2015 Effective Date: June 1, 2014 IMPORTANT

More information

XII Michelangelo Foundation Seminar

XII Michelangelo Foundation Seminar XII Michelangelo Foundation Seminar Paradigm shift? The Food and Drug Administration collaborative project P. Cortazar, Silver Spring, USA FDA Perspective: Moving from Adjuvant to Neoadjuvant Trials in

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Ado-Trastuzumab Emtansine (Trastuzumab-DM1) for Treatment of File Name: Origination: Last CAP Review: Next CAP Review: Last Review: ado_trastuzumab_emtansine_(trastuzumab-dm1)_for_treatment_of_her-2_positivemalignancies

More information

Treatment of Metastatic Breast Cancer. Prof RCCoombes Imperial College London

Treatment of Metastatic Breast Cancer. Prof RCCoombes Imperial College London Treatment of Metastatic Breast Cancer Prof RCCoombes Imperial College London Metastatic Breast Cancer: General Guidelines Specialized oncology nurses (if possible specialized breast nurses) should be part

More information

Page. Objectives: Hormone Therapy Resistance: Challenges and Opportunities. Research Support From Merck

Page. Objectives: Hormone Therapy Resistance: Challenges and Opportunities. Research Support From Merck Hormone Therapy Resistance: Challenges and Opportunities Pamela. N. Munster, MD University of California, San Francisco Financial Disclosures Research Support From Merck Objectives: Understanding the current

More information

pan-canadian Oncology Drug Review Final Clinical Guidance Report Pertuzumab (Perjeta) for Metastatic Breast Cancer August 1, 2013

pan-canadian Oncology Drug Review Final Clinical Guidance Report Pertuzumab (Perjeta) for Metastatic Breast Cancer August 1, 2013 pan-canadian Oncology Drug Review Final Clinical Guidance Report Pertuzumab (Perjeta) for Metastatic Breast Cancer August 1, 2013 DISCLAIMER Not a Substitute for Professional Advice This report is primarily

More information

NeoadjuvantTreatment In BC When, How, Who?

NeoadjuvantTreatment In BC When, How, Who? NeoadjuvantTreatment In BC When, How, Who? Clifford Hudis, M.D. Chief, Breast Cancer Medicine Service, MSKCC Professor of Medicine, Weill Cornell Medical College President, ASCO 15 Potential Benefits Of

More information

Symposium article. Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer: Pivotal trial data

Symposium article. Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer: Pivotal trial data Annals of Oncology 12 (Suppl. I): S57-S62, 2001. 2001 Kluwer Academic Publishers. Primed in the Netherlands. Symposium article Trastuzumab combined with chemotherapy for the treatment of HER2-positive

More information

Adjuvant Systemic Therapy in Early Stage Breast Cancer

Adjuvant Systemic Therapy in Early Stage Breast Cancer Adjuvant Systemic Therapy in Early Stage Breast Cancer Julie R. Gralow, M.D. Director, Breast Medical Oncology Jill Bennett Endowed Professor of Breast Cancer Professor, Global Health University of Washington

More information

breast and OVARIAN cancer

breast and OVARIAN cancer breast and OVARIAN cancer DR DAVID FENNELLY CONSULTANT MEDICAL ONCOLOGIST ST VINCENT S UNIVERSITY HOSPITAL DUBLIN HOW RELEVANT IS ONCOLOGY IN MEDICINE TODAY? Cancer is the second leading cause of death

More information

Adjuvant Chemotherapy + Trastuzumab

Adjuvant Chemotherapy + Trastuzumab Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Adjuvant Chemotherapy + Trastuzumab (Optimal Drugs / Dosage / Trastuzumab) Adjuvant Chemotherapy (Optimal Drugs / Optimal Dosage

More information

Expert Review: The Role of PARP Inhibition in the Treatment of Breast Cancer. Reference Slides

Expert Review: The Role of PARP Inhibition in the Treatment of Breast Cancer. Reference Slides Expert Review: The Role of PARP Inhibition in the Treatment of Breast Cancer Reference Slides Overview BRCA Mutations and Breast Cancer Patients with BRCA mutations have an estimated 55% to 65% cumulative

More information

Choosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer

Choosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer Choosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer Jyoti D. Patel, MD Associate Professor Feinberg School of Medicine Robert H Lurie Comprehensive Cancer Center Northwestern

More information

MEDICAL ONCOLOGY NEWS IN BREAST CANCER 2014

MEDICAL ONCOLOGY NEWS IN BREAST CANCER 2014 MEDICAL ONCOLOGY NEWS IN BREAST CANCER 2014 Dr Thomas Yau Clinical Assistant Professor MBBS(HK), MRCP (UK), FHKCP (Med Onc), FHKAM( Medicine), FRCP(London) Queen Mary Hospital The University of Hong Kong

More information

Estimating and explaining survival time in metastatic breast cancer

Estimating and explaining survival time in metastatic breast cancer Estimating and explaining survival time in metastatic breast cancer Dr Belinda Kiely Medical Oncologist Concord and Campbelltown Hospitals NHMRC Clinical Trials Centre, University of Sydney Clinic this

More information

Existe-t-il un sous groupe à risque qui pourrait bénéficier d une modification de la durée de traitement par trastuzumab? X. Pivot CHRU De Besançon

Existe-t-il un sous groupe à risque qui pourrait bénéficier d une modification de la durée de traitement par trastuzumab? X. Pivot CHRU De Besançon Existe-t-il un sous groupe à risque qui pourrait bénéficier d une modification de la durée de traitement par trastuzumab? X. Pivot CHRU De Besançon In 25 results of 4 Adjuvant Herceptin trials have definitively

More information

Kazuhiro Araki, Yasuo Miyoshi

Kazuhiro Araki, Yasuo Miyoshi Editorial Abundant options to avoid toxicity and alternative strategies for human epidermal growth factor receptor 2-positive and hormone receptor-positive advanced breast cancer Kazuhiro Araki, Yasuo

More information

XII Michelangelo Foundation Seminar

XII Michelangelo Foundation Seminar XII Michelangelo Foundation Seminar The opportunity of the neoadjuvant approach L. Gianni, Milan, I XII Michelangelo Foundation Seminar Milano, October 12, 2012 The opportunity of the neoadjuvant approach

More information

AGO e. V. in der DGGG e.v. sowie in der DKG e.v.

AGO e. V. in der DGGG e.v. sowie in der DKG e.v. AGO e. V. in der DGGG e.v. sowie in der DKG e.v. Guidelines Breast Version 2015.1 www.ago-online.de Disease-Free and Overall Survival in Metastatic Breast Cancer AGO e. V. in der DGGG e.v. sowie in der

More information

TITLE: Systemic Therapy for Patients with Advanced HER2-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline

TITLE: Systemic Therapy for Patients with Advanced HER2-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline TITLE: Systemic Therapy for Patients with Advanced HER2-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Table of Contents Data Supplement 1: Additional Evidence

More information

Metastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian

Metastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in

More information

Updates From San Antonio Breast Cancer Symposium 2017

Updates From San Antonio Breast Cancer Symposium 2017 Updates From San Antonio Breast Cancer Symposium 2017 Rob Coleman University of Sheffield Presentation Outline New Insights into adjuvant endocrine treatment Duration of treatment Perioperative therapy

More information

Key Words. FDA summary Metastatic breast cancer Multidrug resistant Lapatinib Capecitabine

Key Words. FDA summary Metastatic breast cancer Multidrug resistant Lapatinib Capecitabine The Oncologist Regulatory Issues FDA Drug Approval Summary: Lapatinib in Combination with Capecitabine for Previously Treated Metastatic Breast Cancer That Overexpresses HER-2 QIN RYAN, AMNA IBRAHIM, MARTIN

More information

Incorporating Immunotherapy into the treatment of NSCLC

Incorporating Immunotherapy into the treatment of NSCLC Incorporating Immunotherapy into the treatment of NSCLC Suresh S. Ramalingam, MD Roberto C. Goizueta Chair for Cancer Research Assistant Dean for Cancer Research Deputy Director, Winship Cancer Institute

More information

Non-Anthracycline Adjuvant Therapy: When to Use?

Non-Anthracycline Adjuvant Therapy: When to Use? Northwestern University Feinberg School of Medicine Non-Anthracycline Adjuvant Therapy: When to Use? William J. Gradishar MD Betsy Bramsen Professor of Breast Oncology Director, Maggie Daley Center for

More information

Metastatic Breast Cancer What is new? Subtypes and variation?

Metastatic Breast Cancer What is new? Subtypes and variation? Metastatic Breast Cancer What is new? Subtypes and variation? Anne Blaes, MD, MS University of Minnesota, Division of Hematology/Oncology Director, Adult Cancer Survivor Program Current estimates for metastatic

More information

Challenges and Success: Treatment of Metastatic Breast Cancer 2012

Challenges and Success: Treatment of Metastatic Breast Cancer 2012 Challenges and Success: Treatment of Metastatic Breast Cancer 2012 Hope S. Rugo University of California San Francisco Helen Diller Family Comprehensive Cancer Center This presentation is the intellectual

More information

Technology Hurdles: Drug Developer Perspective

Technology Hurdles: Drug Developer Perspective Technology Hurdles: Drug Developer Perspective Robert Mass, MD Senior Director Genentech, Inc. June 8, 2009 Diagnostic challenges Genentech has been committed to personalized drug development in oncology

More information

Novel Preoperative Therapies for HER2-Positive Breast Cancer. Debu Tripathy, MD University of Southern California Norris Comprehensive Cancer Center

Novel Preoperative Therapies for HER2-Positive Breast Cancer. Debu Tripathy, MD University of Southern California Norris Comprehensive Cancer Center Novel Preoperative Therapies for HER2-Positive Breast Cancer Debu Tripathy, MD University of Southern California Norris Comprehensive Cancer Center Key Findings to Date in the Neoadjuvant Therapy of HER2+

More information